ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research

March 2, 2021

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. The consideration represents an approximately 30% premium to PRA’s closing price as of February 23rd, 2021.

The transaction brings together two high-quality, innovative and growing organisations with similar cultures and a shared focus on high quality and efficient clinical trial execution from Phase 1 to post-approval studies.


Read the full article at: https://www.businesswire.com/news/home/20210224005484/en/ICON-to-Acquire-PRA-Health-Sciences-Creating-a-World-Leader-in-Healthcare-Intelligence-and-Clinical-Research#.YDZJEgExMLE.linkedin


Copyright © 2020 · Catawba Research, LLC